Close Menu

research consortium

The UK Coronavirus Immunology Consortium is one of three projects to receive a total of £8.4 million from UKRI and NIHR to study immune response to the novel coronavirus.

The effort, called SPHERES, aims to monitor changes in the virus to support public health research and diagnostic and therapeutic development.

With $2.5 million in initial philanthropy funding, the consortium plans to launch several research projects and establish a data commons for storing and sharing results. 

The newly launched EndPandemic National Data Consortium brings together seven life sciences and bioinformatics firms in search of treatments and vaccines.

Blueprint Genetics, recently acquired by Quest Diagnostics in January, will base the 600-gene panel on its whole-exome sequencing capability.

Big Blue's IBM Research and Watson divisions are teaming with several national consortia to unlock and share molecular and clinical coronavirus data on HPC platforms.

The project's total budget is expected to exceed $1.5 million with backing from the Israeli Innovation Authority and international technology firm BATM.

A nationwide, multi-agency effort to sequence the virus causing COVID-19 is a logistical nightmare, but experts say the UK is well situated to succeed.

The consortium, which spans more than a dozen UK cities, will sequence patient samples to understand the spread and evolution of the novel coronavirus.

The company plans to offer four new products by the end of the year, including four targeted transcriptomic panels and IHC compatibility for Visium.

Pages

Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.

Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.

The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.

This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.